Sandoz, Taiwan’s TLC Ink Commercialization Deal For AmBisome Generic In U.S., EU
This article was originally published in PharmAsia News
Sandoz will commercialize TLC’s liposomal amphotericin B product, a generic of Gilead’s AmBisome, in the U.S. and EU.
You may also be interested in...
HONG KONG - A cash injection from a U.S. venture capital firm may help a Taiwanese developer of drug delivery systems better compete on a global scale as it moves towards an initial public offering
Taiwan Liposome Co. Ltd. has the funds and team to reach outside of its base in Taiwan to turn old drugs into new products and is looking for opportunities at Asia-specific product applications.
Generon in Shanghai was founded by former Hutchison MediPharma employees to target a niche market between expensive import drugs and lower quality domestic products.